702 filings
Page 14 of 36
8-K
og1hom3638h7
27 Apr 17
Acorda Provides Financial and Pipeline Update for First Quarter 2017
12:00am
8-K
8kc0w2sea86sfpf
6 Apr 17
Cost Associated with Exit or Disposal Activities
12:00am
8-K
cau14
31 Mar 17
U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling
12:00am
8-K
pr1od8foo
29 Mar 17
Acorda Announces Long-Term Safety Data for CVT-301
12:00am
8-K
vakkglfg mlgnkg4e5h
9 Mar 17
Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA® Patents
12:00am
8-K
dcyke3f
21 Feb 17
Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors
12:00am
8-K
hmabxy7 vpbkhcn9
14 Feb 17
Results of Operations and Financial Condition
12:00am
8-K
3us4cz1u zjlw2
10 Feb 17
Other Events
12:00am
8-K
sljyiq612m2h
9 Feb 17
Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301
12:00am
8-K
8u00oy
9 Jan 17
Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial
12:00am
8-K
lfsq6je eyirjtiqr0p
21 Nov 16
Acorda to Discontinue Development of Dalfampridine for Treatment of
12:00am
8-K
xqvkh42 b1
27 Oct 16
Acorda Provides Financial and Pipeline Update for Third Quarter 2016
12:00am
UPLOAD
74x11p8p3tyd
25 Oct 16
Letter from SEC
12:00am
CT ORDER
9i30w1qd4a89kdnk
17 Oct 16
Confidential treatment order
12:00am
CORRESP
drm3wpyvwh38
13 Oct 16
Correspondence with SEC
12:00am
8-K
j4vf0kt
13 Oct 16
Other Events
12:00am
UPLOAD
u2vnfv07iq 05xw2bny
5 Oct 16
Letter from SEC
12:00am